Abstract 【Objective】To investigate the value of morinda officinalis oligosaccharide capsules in the treatment of elderly patients with mild depression after stroke. 【Methods】A total of 90 elderly patients with mild depression after stroke who were admitted to two hospitals were randomly divided into two groups, with 45 cases in each group. The control group was treated with escitalopram, and the observation group was additionally treated with morinda officinalis oligosaccharide capsules on the basis of the control group. The clinical efficacy of the two groups was compared, and the scores of the Self-rating Depression Scale (SDS), Hamilton Depression Scale (HAMD), Simple Social Coping Scale (SCSQ) and Montreal Cognitive Assessment Scale (MoCA) score changes, and the incidence of adverse reactions in the two groups was observed. 【Results】The total effective rate in the observation group was 95.56%, which was higher than 82.22% in the control group (P<0.05). There was no significant difference in the scores of SDS, HAMD, MoCA and SCSQ between the two groups before treatment (P>0.05). After treatment, the scores of SDS, HAMD and negative coping style in the two groups were lower than those before treatment (P<0.05), while the scores of MoCA and positive coping style were higher than those before treatment. The scores of SDS, HAMD and negative coping style of post-treatment in the observation group were lower than those in the control group (P<0.05); And the scores of MoCA and positive coping style in the observation group were higher than those in the control group (P<0.05). The incidence of adverse reactions in the observation group was 11.11% (5/45), which was not significantly different from 8.89% (4/45) in the control group (P>0.05). 【Conclusion】Morinda oligosaccharide capsules have significant curative effect in the treatment of elderly patients with mild depression after stroke, which can improve the antidepressant effect, improve the coping style of patients, and will not increase the risk of adverse reactions.
AI Wen-jun,GAO Ying. Application of Morinda Officinalis Oligosaccharide Capsules in Treatment of Elderly Patients with Mild Depression after Stroke[J]. JOURNAL OF CLINICAL RESEARCH, 2022, 39(10): 1486-1488.
[1] ZHAO F Y,YUE Y Y,LI L,et al.Clinical practice guidelines for post-stroke depression in China[J].Braz J Psychiatry,2018,40(3):325-334.
[2] KUMAR S.Sobering news about post-stroke depression[J].Lancet Psychiatry,2017,4(1):2-3.
[3] XU J H,JIANG P.Efficacy of escitalopram oxalate for patients with post-stroke depression[J].Medicine (Baltimore),2018,97(14):219.
[4] JIANG H,XIAO L,JIN K,et al.Estrogen administration attenuates poststroke depression by enhancing CREB/BDNF/TrkB signaling in the rat hippocampus[J].Exp Ther Med,2021,21(5):433.
[5] 邓小娟,敖素华.巴戟天寡糖胶囊治疗抑郁症的Meta分析[J].中成药,2020,42(2):541-546.
[6] 中华医学会神经病学分会,中华医学会神经病学分会脑血管病学组.中国急性缺血性脑卒中诊治指南2014[J].中华神经科杂志,2015,48(4):246-257.
[7] 中华医学会精神病学分会.中国精神障碍分类与诊断标准[M].第3版.济南:山东科学技术出版社,2001:87-89.
[8] 李文波,许明智,高亚丽.汉密顿抑郁量表6项版本(HAMD-6)的信度及效度研究[J].中国神经精神疾病杂志,2006,32(2):117-120.
[9] 段泉泉,胜利.焦虑及抑郁自评量表的临床效度[J].中国心理卫生杂志,2012,26(9):676-679.
[10] 朱宇航,郭继志,罗盛,等.简易应对方式问卷在老年人群体中的修订及信效度检验[J].中国卫生统计,2016,33(4):660-664.
[11] 陈宁,何俐.蒙特利尔认知评估(MoCA)的研究和应用概况[J].中国神经精神疾病杂志,2009,35(10):632-634.
[12] LI A,TIAN J,YANG J,et al.Expression of fibroblast growth factor 9 and its receptors in the dentate gyrus of hippocampus in poststroke depression rats[J].Neuroreport,2021,32(4):321-325.
[13] 胡燮军,冯虹,李松涛,等.艾司西酞普兰治疗难治性抑郁症的效果观察[J].中国基层医药,2020,27(14):1725-1728.
[14] 于丽燕,谢姗姗.脑波同步穴位刺激联合巴戟天寡糖胶囊对老年抑郁症患者的影响[J].实用心脑肺血管病杂志,2019,27(2):73-76.
[15] 陈建波,肖凡.巴戟天寡糖胶囊治疗轻、中度抑郁症的疗效观察[J].陕西中医,2016,37(8):1029-1031.
2022, Vol. 39 
